Siglec‐8 and Siglec‐9 have been shown to play a role in the resolution of ongoing inflammation in asthma and COPD, respectively, with polymorphisms of SIGLEC8 and SIGLEC9 associated with disease severity.40, 42 Circulating levels of soluble Siglec‐9 have been proposed to impair disease resolution in COPD patients by ‘mopping‐up’ ligands for Siglec‐9 that would otherwise tone down inflammatory responses of alveolar neutrophils. Here, SIGLEC8 is linked to chronic obstructive pulmonary disease.